The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Genomic complexity and degree of marrow independence of malignant plasma cells in the context of EMD
Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on a study analyzing the largest sequencing cohort of focal intra-medullary lesions (IMD) and para-medullary (PMD) and extra-medullary disease (EMD) to date, comparing with paired bone marrow (BM) samples where available. Dr Shah highlights that a greater number of copy number aberrations, increased mutational burden, and greater genomic complexity were observed in plasmacytomas compared to the BM. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This abstract is being presented by Kylie McLachlan on behalf of our group, which includes Dr Francesco Maura and Dr. Niels Weinhold and Dr. Usmani, as well as other co-authors. What we did in this study is sequence whole genome sequencing or whole exome sequencing or targeted sequencing of plasmacytomas, meaning tumors in either the bone or extramedullary. So, paramedullary or extramedullary plasmacytomas, as well as bone marrow sequencing...
This abstract is being presented by Kylie McLachlan on behalf of our group, which includes Dr Francesco Maura and Dr. Niels Weinhold and Dr. Usmani, as well as other co-authors. What we did in this study is sequence whole genome sequencing or whole exome sequencing or targeted sequencing of plasmacytomas, meaning tumors in either the bone or extramedullary. So, paramedullary or extramedullary plasmacytomas, as well as bone marrow sequencing. We compared genomic changes in the bone marrow to the plasmacytomas, and we see that there is increased copy number aberrations, increased mutational burden, and genomic complexity in the plasmacytomas compared to the bone marrow, suggesting that disease is arising from the copy number aberrations and may be more complex in its genomic characteristics. We present this data on about over almost 200 plasmacytomas samples and a large number of bone marrow samples as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sanofi: Honoraria; Bristol Myers Squibb: Research Funding; Janssen: Honoraria, Research Funding.
